Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.18
MNK's Cash to Debt is ranked higher than
50% of the 909 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.55 vs. MNK: 0.18 )
MNK' s 10-Year Cash to Debt Range
Min: 0.18   Max: No Debt
Current: 0.18

Equity to Asset 0.39
MNK's Equity to Asset is ranked higher than
53% of the 790 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.60 vs. MNK: 0.39 )
MNK' s 10-Year Equity to Asset Range
Min: 0.35   Max: 0.39
Current: 0.39

0.35
0.39
Z-Score: 1.14
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -11.18
MNK's Operating margin (%) is ranked higher than
56% of the 857 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.33 vs. MNK: -11.18 )
MNK' s 10-Year Operating margin (%) Range
Min: -11.18   Max: 11.91
Current: -11.18

-11.18
11.91
Net-margin (%) -12.57
MNK's Net-margin (%) is ranked higher than
56% of the 857 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.06 vs. MNK: -12.57 )
MNK' s 10-Year Net-margin (%) Range
Min: -12.57   Max: 7.45
Current: -12.57

-12.57
7.45
ROE (%) -15.67
MNK's ROE (%) is ranked higher than
57% of the 879 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.84 vs. MNK: -15.67 )
MNK' s 10-Year ROE (%) Range
Min: -10.28   Max: 9.37
Current: -15.67

-10.28
9.37
ROA (%) -5.17
MNK's ROA (%) is ranked higher than
58% of the 912 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.12 vs. MNK: -5.17 )
MNK' s 10-Year ROA (%) Range
Min: -3.89   Max: 3.31
Current: -5.17

-3.89
3.31
ROC (Joel Greenblatt) (%) -18.02
MNK's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 907 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.05 vs. MNK: -18.02 )
MNK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -19.35   Max: 19.2
Current: -18.02

-19.35
19.2
» MNK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

MNK Guru Trades in Q4 2013

Jim Simons 279,900 sh (New)
Jean-Marie Eveillard 187 sh (New)
Chuck Royce 402,005 sh (+14.53%)
John Paulson 5,640,000 sh (unchged)
Vanguard Health Care Fund 500,325 sh (unchged)
Eric Mindich 900,000 sh (unchged)
Mario Gabelli Sold Out
Pioneer Investments Sold Out
Jana Partners 3,312,546 sh (-14.83%)
» More
Q1 2014

MNK Guru Trades in Q1 2014

Paul Tudor Jones 360,100 sh (New)
Steven Cohen 557,066 sh (New)
Pioneer Investments 121,494 sh (New)
Jean-Marie Eveillard 187 sh (unchged)
Vanguard Health Care Fund Sold Out
Eric Mindich Sold Out
John Paulson 5,636,800 sh (-0.06%)
Jana Partners 3,267,691 sh (-1.35%)
Jim Simons 254,100 sh (-9.22%)
Chuck Royce 178,505 sh (-55.6%)
» More
Q2 2014

MNK Guru Trades in Q2 2014

Paul Singer 916,000 sh (New)
Richard Perry 134,322 sh (New)
Chase Coleman 729,373 sh (New)
Mario Gabelli 2,656 sh (New)
Jana Partners 5,725,711 sh (+75.22%)
John Paulson 6,724,800 sh (+19.3%)
Jean-Marie Eveillard 187 sh (unchged)
Chuck Royce Sold Out
Pioneer Investments 120,663 sh (-0.68%)
Jim Simons 238,900 sh (-5.98%)
Paul Tudor Jones 308,900 sh (-14.22%)
» More
Q3 2014

MNK Guru Trades in Q3 2014

John Hussman 67,275 sh (New)
Chuck Royce 23,407 sh (New)
Joel Greenblatt 115,541 sh (New)
Steven Cohen 31,900 sh (New)
Richard Perry 1,150,000 sh (+756.15%)
Mario Gabelli 7,134 sh (+168.6%)
Jim Simons 359,502 sh (+50.48%)
John Paulson 9,000,000 sh (+33.83%)
Jean-Marie Eveillard 187 sh (unchged)
Paul Singer Sold Out
Chase Coleman Sold Out
Jana Partners Sold Out
Pioneer Investments 120,582 sh (-0.07%)
Paul Tudor Jones 24,849 sh (-91.96%)
» More
» Details

Insider Trades

Latest Guru Trades with MNK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Richard Perry 2014-09-30 Add 756.15%3.36%$68.12 - $90 $ 105.9936%1150000
John Paulson 2014-09-30 Add 33.83%0.86%$68.12 - $90 $ 105.9936%9000000
John Hussman 2014-09-30 New Buy0.52%$68.12 - $90 $ 105.9936%67275
Joel Greenblatt 2014-09-30 New Buy0.1%$68.12 - $90 $ 105.9936%115541
Mario Gabelli 2014-09-30 Add 168.6%$68.12 - $90 $ 105.9936%7134
John Paulson 2014-06-30 Add 19.3%0.37%$60.28 - $82.7 $ 105.9947%6724800
Richard Perry 2014-06-30 New Buy0.3%$60.28 - $82.7 $ 105.9947%134322
Mario Gabelli 2014-06-30 New Buy$60.28 - $82.7 $ 105.9947%2656
Vanguard Health Care Fund 2014-03-31 Sold Out 0.08%$50.7 - $72.81 $ 105.9970%0
Mario Gabelli 2013-12-31 Sold Out $42.01 - $53.47 $ 105.99122%0
Jean-Marie Eveillard 2013-12-31 New Buy$42.01 - $53.47 $ 105.99122%187
John Paulson 2013-09-30 New Buy1.6%$41.51 - $47.16 $ 105.99142%5640000
Vanguard Health Care Fund 2013-09-30 New Buy0.08%$41.51 - $47.16 $ 105.99142%500325
Mario Gabelli 2013-09-30 New Buy$41.51 - $47.16 $ 105.99142%13360
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 31.06
MNK's Forward P/E is ranked higher than
82% of the 962 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 60.61 vs. MNK: 31.06 )
N/A
P/B 1.25
MNK's P/B is ranked higher than
92% of the 962 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.81 vs. MNK: 1.25 )
MNK' s 10-Year P/B Range
Min: 1   Max: 3.59
Current: 1.25

1
3.59
P/S 2.71
MNK's P/S is ranked higher than
79% of the 962 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.97 vs. MNK: 2.71 )
MNK' s 10-Year P/S Range
Min: 1.11   Max: 2.73
Current: 2.71

1.11
2.73
PFCF 31.73
MNK's PFCF is ranked higher than
89% of the 962 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MNK: 31.73 )
MNK' s 10-Year PFCF Range
Min: 21.68   Max: 45.83
Current: 31.73

21.68
45.83
POCF 20.07
MNK's POCF is ranked higher than
85% of the 962 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 39.14 vs. MNK: 20.07 )
MNK' s 10-Year POCF Range
Min: 12.38   Max: 45.83
Current: 20.07

12.38
45.83
EV-to-EBIT -54.87
MNK's EV-to-EBIT is ranked lower than
51% of the 962 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.50 vs. MNK: -54.87 )
MNK' s 10-Year EV-to-EBIT Range
Min: -43.5   Max: 52.1
Current: -54.87

-43.5
52.1
Current Ratio 2.29
MNK's Current Ratio is ranked higher than
69% of the 862 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. MNK: 2.29 )
MNK' s 10-Year Current Ratio Range
Min: 2.29   Max: 2.31
Current: 2.29

2.29
2.31
Quick Ratio 1.85
MNK's Quick Ratio is ranked higher than
72% of the 862 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. MNK: 1.85 )
MNK' s 10-Year Quick Ratio Range
Min: 1.64   Max: 1.85
Current: 1.85

1.64
1.85
Days Inventory 113.08
MNK's Days Inventory is ranked higher than
80% of the 962 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 149.40 vs. MNK: 113.08 )
MNK' s 10-Year Days Inventory Range
Min: 62.36   Max: 109.13
Current: 113.08

62.36
109.13
Days Sales Outstanding 78.39
MNK's Days Sales Outstanding is ranked higher than
75% of the 962 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 86.21 vs. MNK: 78.39 )
MNK' s 10-Year Days Sales Outstanding Range
Min: 66.36   Max: 78.39
Current: 78.39

66.36
78.39

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.52
MNK's Price/Median PS Value is ranked higher than
66% of the 962 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.33 vs. MNK: 1.52 )
MNK' s 10-Year Price/Median PS Value Range
Min: 0.65   Max: 1.29
Current: 1.52

0.65
1.29
Earnings Yield (Greenblatt) -1.80
MNK's Earnings Yield (Greenblatt) is ranked higher than
60% of the 907 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. MNK: -1.80 )
MNK' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.9   Max: 5
Current: -1.8

1.9
5

Analyst Estimate

Sep15 Sep16 Sep17
Revenue(Mil) 3,673 3,879 4,152
EPS($) 6.70 3.45 9.50
EPS without NRI($) 6.70 3.45 9.50

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:MCD.Germany,
Mallinckrodt PLC develops, manufactures, markets and distributes specialty pharmaceutical products and diagnostic imaging agents. Its specialty pharmaceutical products are sold to wholesalers and retail drugstore chains. The Company's Specialty Pharmaceuticals segment includes branded and generic drugs, and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. The Company's products include Intrathecal Product used in the management of cerebral or spinal spasticity. The Company's nonsteroidal anti-inflammatory drug (NSAID) portfolio helps address the signs and symptoms of painful condition. PENNSAID, is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s). The Opioid products include EXALGO. It is an Extended-Release Tablets indicated for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time. The Central Nervous Systems' products include Anafranil, indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD). The Global Medical Imaging products includes Optisuite, Optibolus Bolus Shaping Software, Ready-Box, Ultra-Technekow DTE Generator, Octreoscan, and Technescan MAG3.
» More Articles for MNK

Headlines

Articles On GuruFocus.com
Paulson Bets Again On Mallinckrodt Aug 07 2014 
Dumb Investment of the Week: Mallinckrodt PLC Jul 17 2014 
Mallinckrodt Acquired San Diego Pharma and Much More Mar 21 2014 
Can Malllinckrodt Keep on Crushing Expectations? Mar 19 2014 
Should You Buy Actavis? Mar 18 2014 
Weekly 3-Year Low Highlight: EW, NUAN, MNK, CROX, IRDM Nov 03 2013 


More From Other Websites
Intercept Pharmaceuticals' OCA Now Breakthrough Therapy - Analyst Blog Jan 30 2015
Dr. Reddy's (RDY) Q3 Earnings Down 7% Y/Y, Revenues Up - Analyst Blog Jan 30 2015
Teva Gains FDA Nod for Generic of AstraZeneca's Nexium - Analyst Blog Jan 28 2015
Actavis to Buy Auden Mckenzie, Boost Generic Portfolio - Analyst Blog Jan 27 2015
Will Oncology Products Drive Bristol-Myers (BMY) Earnings? - Analyst Blog Jan 23 2015
MALLINCKRODT PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 23 2015
Why the Earnings Streak Will Continue for Mallinckrodt public limited (MNK) - Tale of the Tape Jan 23 2015
Mallinckrodt plc Announces Share Repurchase Program Jan 23 2015
Mallinckrodt plc Announces Share Repurchase Program Jan 23 2015
10 World Stocks, Including 3 New Highs And 3 Bases Jan 13 2015
Friday's Market Recap Jan 09 2015
Jim Cramer's Top Stock Picks: AAL SAVE EW MNK KR Jan 09 2015
Cramer: Party with these rock star stocks Jan 08 2015
Mallinckrodt Builds Leadership To Support Continued Growth Jan 07 2015
Mallinckrodt Builds Leadership To Support Continued Growth Jan 07 2015
2014's Biggest Stock Winners: Is There Any Gas Left in the Tank? Jan 07 2015
Mallinckrodt plc to Report First Quarter Fiscal 2015 Results on February 3, 2015 Jan 05 2015
Mallinckrodt plc to Report First Quarter Fiscal 2015 Results on February 3, 2015 Jan 05 2015
Adage Capital adds a new position in Mallinckrodt Jan 05 2015
New York Times report on 'dead malls' uses Owings Mills as prime example Jan 05 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK